- Trials with a EudraCT protocol (3,448)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
3,448 result(s) found for: Antibody Response.
Displaying page 1 of 173.
EudraCT Number: 2014-003007-29 | Sponsor Protocol Number: 2014-0087054 | Start Date*: 2015-08-12 |
Sponsor Name:University Hospitals Leuven, department of pediatrics | ||
Full Title: The Polysaccharide Antibody Response Study: Typhim Vi response and allohemagglutinins versus Pneumo 23 vaccine response in the diagnosis of Specific Polysaccharide Antibody Deficiency. | ||
Medical condition: Specific polysaccharide antibody deficiency. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000633-14 | Sponsor Protocol Number: SZÚ/01591/2021 | Start Date*: 2021-03-30 | |||||||||||
Sponsor Name:Státní zdravotní ústav | |||||||||||||
Full Title: DYNAMICS OF POSTVACCINATION ANTI- SARS-COV-2 ANTIBODY RESPONSE IN EMPLOYES OF THE NATIONAL INSTITUTE OF PUBLIC HEALTH AND VOLUNTARIES 1-2021 | |||||||||||||
Medical condition: antibody response following vaccine application | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003804-42 | Sponsor Protocol Number: INCENTIVE-QIV2-EU | Start Date*: 2021-10-04 |
Sponsor Name:Helse Bergen HF | ||
Full Title: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years old | ||
Medical condition: Immune response to infuenza vaccine in young children | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002613-34 | Sponsor Protocol Number: NL76336.041.21 | Start Date*: 2021-06-30 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome | ||
Medical condition: Persons with Down syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002014-14 | Sponsor Protocol Number: COV-PBO-MO28 | Start Date*: 2021-04-20 |
Sponsor Name:Fakultní nemocnice Hradec Králové | ||
Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002586-21 | Sponsor Protocol Number: X04-MMRr-301 | Start Date*: 2004-12-23 |
Sponsor Name:Aventis Pasteur MSD SNC | ||
Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® when administered concomitantly by in... | ||
Medical condition: Not applicable - Healthy subjects | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002946-11 | Sponsor Protocol Number: 111852 | Start Date*: 2015-05-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and M... | ||
Medical condition: Booster immunization of healthy children 4-6 years of age against diphtheria, tetanus, pertussis and polio diseases. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-002767-95 | Sponsor Protocol Number: 12/0161 | Start Date*: 2013-06-17 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous... | |||||||||||||
Medical condition: Cytomegalovirus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003370-41 | Sponsor Protocol Number: VAT00002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003286-37 | Sponsor Protocol Number: D5180C00031 | Start Date*: 2022-12-22 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent I... | |||||||||||||
Medical condition: Moderate to Severe Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000924-18 | Sponsor Protocol Number: M14P6 | Start Date*: 2005-09-07 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vacc... | ||
Medical condition: Healthy subjects without known medical conditions will be vaccinated against N. menigitidis serogroup C. Active prevention of menigococcal C disease caused by Neisseria menigitidis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003790-10 | Sponsor Protocol Number: MEQ00065 | Start Date*: 2019-05-28 | |||||||||||
Sponsor Name:Sanofi Pasteur | |||||||||||||
Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age | |||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004129-27 | Sponsor Protocol Number: X06-MMRV-302 | Start Date*: 2006-12-13 |
Sponsor Name:Sanofi Pasteur MSD | ||
Full Title: An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (... | ||
Medical condition: The study will involve healthy children. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004891-33 | Sponsor Protocol Number: T33/2021 | Start Date*: 2022-04-13 |
Sponsor Name:Turku University Hospital | ||
Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005059-25 | Sponsor Protocol Number: V59P6E1 | Start Date*: 2014-11-25 |
Sponsor Name:Novartis Vaccines &Diagnostics, Inc. | ||
Full Title: A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously V... | ||
Medical condition: Novartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis A, C, W-135 and Y. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-003068-29 | Sponsor Protocol Number: P170934J | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2) | |||||||||||||
Medical condition: Asplenic patients at risk for invasive pneumococcal diseases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001118-40 | Sponsor Protocol Number: NL69183.xxx.19 | Start Date*: 2019-08-22 |
Sponsor Name:Department of Pulmonology | ||
Full Title: Response to pneumococcal polysaccharide vaccination in healthy adults | ||
Medical condition: immunodeficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003941-24 | Sponsor Protocol Number: Td528 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR SA | |||||||||||||||||||||||
Full Title: Immunogenicity and Safety of Sanofi Pasteur’s Tdap Combined Vaccine (ADACEL) as a Booster Dose, versus Local DT Vaccine in Healthy Children or versus Local Td Vaccine in Healthy Adolescents and Adu... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006083-11 | Sponsor Protocol Number: 110699 to 110704 | Start Date*: 2009-03-23 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccin... | ||
Medical condition: Adult subjects who received a primary vaccination course with Twinrix Adult following a two-dose schedule or Twinrix Junior following a three-dose schedule as adolescents (12-15 years) approximate... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003950-41 | Sponsor Protocol Number: Td536 | Start Date*: 2016-01-13 | |||||||||||||||||||||
Sponsor Name:SANOFI PASTEUR SA | |||||||||||||||||||||||
Full Title: Immunogenicity and safety of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) given intramuscularly compared to Diphtheria and Tetanus toxoids adsorbed... | |||||||||||||||||||||||
Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.